exRNAdisease

Entry Detail

---



General Information

Database ID: exR0270549 RNA Name: hsa-miR-7-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 4770700 End Site(bp): 4770723 External Links: hsa-miR-7-5p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RCC2 chr1 17406760 17439677 - GNA12 chr7 2728105 2844308 - RAB29 chr1 205767986 205775482 - TSPAN14 chr10 80454166 80533124 + INTS2 chr17 61865367 61928016 - ACVR1B chr12 51951699 51997078 + RPS6KB1 chr17 59893046 59950574 + SCD chr10 100347233 100364826 + INSR chr19 7112255 7294414 - SLC25A44 chr1 156193932 156212796 + KMT2D chr12 49018975 49059774 - ORAI1 chr12 121626550 121642677 + ATXN1 chr6 16299112 16761491 - NAPA chr19 47487637 47515091 - HP1BP3 chr1 20740266 20787323 - SETD7 chr4 139495941 139606699 - PLXNA1 chr3 126988594 127037392 + KLHL18 chr3 47282917 47346816 + IRS2 chr13 109752695 109786583 - CBL chr11 119206298 119313926 + VPS4A chr16 69311350 69326939 + DNAJC9 chr10 73183362 73247255 - PATL1 chr11 59636716 59669037 - MEPCE chr7 100428790 100434118 + FYCO1 chr3 45917899 45995824 - JAM3 chr11 134069071 134152001 + HMGA2 chr12 65824131 65966295 + TM4SF1 chr3 149369022 149377692 - DHCR24 chr1 54849627 54887195 - RUSC1 chr1 155320894 155331114 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC105339.2 chr15 82752884 82757208 + AL096870.2 chr14 24209646 24215987 - AL590617.2 chr6 138692548 138697288 + MIR497HG chr17 7015818 7019659 - OIP5-AS1 chr15 41283990 41309737 + SNHG1 chr11 62851984 62855953 - TBC1D3P1-DHX40P1 chr17 59962363 60018975 - U91328.1 chr6 25992641 26001775 + XIST chrX 73820649 73852723 - ZFAS1 chr20 49278178 49299600 + Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.